- Home
- NVOS vs SBFM Comparison
NVOS vs SBFM Comparison
Compare NVOS & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVOS
- SBFM
- Stock Information
- Founded
- NVOS 2000
- SBFM 2006
- Country
- NVOS United States
- SBFM United States
- Employees
- NVOS N/A
- SBFM N/A
- Industry
- NVOS Assisted Living Services
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- NVOS Health Care
- SBFM Health Care
- Exchange
- NVOS Nasdaq
- SBFM Nasdaq
- Market Cap
- NVOS 5.6M
- SBFM 3.7M
- IPO Year
- NVOS 2017
- SBFM N/A
- Fundamental
- Price
- NVOS $0.23
- SBFM $3.14
- Analyst Decision
- NVOS
- SBFM
- Analyst Count
- NVOS 0
- SBFM 0
- Target Price
- NVOS N/A
- SBFM N/A
- AVG Volume (30 Days)
- NVOS 326.8K
- SBFM 90.8K
- Earning Date
- NVOS 12-12-2024
- SBFM 11-11-2024
- Dividend Yield
- NVOS N/A
- SBFM N/A
- EPS Growth
- NVOS N/A
- SBFM N/A
- EPS
- NVOS N/A
- SBFM N/A
- Revenue
- NVOS $13,516,958.00
- SBFM $30,481,982.00
- Revenue This Year
- NVOS N/A
- SBFM $86.70
- Revenue Next Year
- NVOS N/A
- SBFM $126.76
- P/E Ratio
- NVOS N/A
- SBFM N/A
- Revenue Growth
- NVOS 1102.98
- SBFM 109.82
- 52 Week Low
- NVOS $0.20
- SBFM $2.42
- 52 Week High
- NVOS $3.45
- SBFM $660.00
- Technical
- Relative Strength Index (RSI)
- NVOS 38.13
- SBFM 52.62
- Support Level
- NVOS $0.20
- SBFM $2.85
- Resistance Level
- NVOS $0.31
- SBFM $3.05
- Average True Range (ATR)
- NVOS 0.03
- SBFM 0.14
- MACD
- NVOS 0.00
- SBFM 0.03
- Stochastic Oscillator
- NVOS 27.18
- SBFM 85.29
About NVOS Novo Integrated Sciences Inc.
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.